Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) – Stock analysts at Oppenheimer raised their Q2 2023 EPS estimates for shares of Seres Therapeutics in a note issued to investors on Wednesday, November 2nd. Oppenheimer analyst M. Breidenbach now expects that the biotechnology company will post earnings of $0.49 per share for the quarter, up from their previous estimate of $0.44. The consensus estimate for Seres Therapeutics' current full-year earnings is ($2.12) per share.
Get Seres Therapeutics alerts:Seres Therapeutics (NASDAQ:MCRB – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). Seres Therapeutics had a negative return on equity of 100.32% and a negative net margin of 75.48%. The firm had revenue of $3.44 million during the quarter, compared to analyst estimates of $12.29 million.
A number of other brokerages have also commented on MCRB. Piper Sandler boosted their price objective on shares of Seres Therapeutics from $7.00 to $9.00 and gave the stock an "overweight" rating in a report on Wednesday, September 7th. Chardan Capital dropped their target price on shares of Seres Therapeutics from $16.00 to $12.00 in a research report on Thursday, August 4th. Finally, StockNews.com raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 29th.Seres Therapeutics Stock Performance
Shares of MCRB stock opened at $8.14 on Friday. Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a market capitalization of $1.01 billion, a P/E ratio of -3.46 and a beta of 2.81. The company's fifty day moving average price is $6.61 and its two-hundred day moving average price is $4.95.
Institutional Investors Weigh In On Seres Therapeutics
A number of institutional investors have recently modified their holdings of MCRB. Janney Montgomery Scott LLC grew its position in Seres Therapeutics by 2.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 84,800 shares of the biotechnology company's stock worth $544,000 after purchasing an additional 2,000 shares during the last quarter. Credit Suisse AG grew its position in Seres Therapeutics by 4.1% in the 2nd quarter. Credit Suisse AG now owns 90,359 shares of the biotechnology company's stock worth $309,000 after purchasing an additional 3,532 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Seres Therapeutics by 54.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,668 shares of the biotechnology company's stock worth $76,000 after purchasing an additional 3,775 shares during the last quarter. Strs Ohio grew its position in Seres Therapeutics by 4.2% in the 1st quarter. Strs Ohio now owns 102,800 shares of the biotechnology company's stock worth $731,000 after purchasing an additional 4,100 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its position in Seres Therapeutics by 38.4% in the 1st quarter. E Fund Management Co. Ltd. now owns 14,871 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 4,127 shares during the last quarter. Institutional investors own 96.09% of the company's stock.
Insider Activity at Seres Therapeutics
In related news, insider David S. Ege sold 5,012 shares of the business's stock in a transaction dated Monday, October 31st. The shares were sold at an average price of $7.93, for a total transaction of $39,745.16. Following the completion of the sale, the insider now owns 46,734 shares of the company's stock, valued at approximately $370,600.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.20% of the company's stock.
About Seres Therapeutics
(Get Rating)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Featured Stories
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.